Articles from Septerna, Inc.

Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 10:30 a.m. ET in Boston.

Trial decision follows unanticipated events of elevated unconjugated bilirubin levels

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Gil Labrucherie, CFA, J.D., as Chief Financial Officer. Mr. Labrucherie is a seasoned biopharma executive with more than 25 years of senior leadership experience in finance and legal roles for public biopharmaceutical and technology companies.

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 3:45 p.m. PT in San Francisco.

Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, today announced the closing of its upsized initial public offering (IPO) of 18,400,000 shares of its common stock at a public offering price of $18.00 per share, which includes an additional 2,400,000 shares issued upon the full exercise by the underwriters of their option to purchase additional shares. All of the shares were offered by Septerna.

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, today announced the pricing of its upsized initial public offering of 16,000,000 shares of its common stock at a public offering price of $18.00 per share. In addition, Septerna has granted the underwriters a 30-day option to purchase up to an additional 2,400,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by Septerna, and the common stock is expected to begin trading on the Nasdaq Global Market on October 25, 2024, under the ticker symbol “SEPN.”

Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, presented new preclinical data from its parathyroid hormone 1 receptor (PTH1R) program in a poster presentation at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting held from September 27-30, 2024, in Toronto, ON, Canada.

Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced the appointments of multiple senior leaders to its drug development team, including Jae Kim, M.D., FACC, as Chief Medical Officer. Dr. Kim is an accomplished healthcare executive with extensive experience in advancing novel therapies across multiple therapeutic areas and will play a central role in leading the company’s clinical development strategy. Septerna also announced the appointments of Monica Gangal as Vice President of Clinical Operations and Matthew Holdren, Ph.D., DABT, as Vice President of Toxicology.

Septerna, a biotechnology company discovering and advancing novel oral small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced that it has signed a definitive asset purchase agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) under which Vertex has acquired an undisclosed discovery-stage GPCR program.

Septerna, a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced the establishment of its cross-functional scientific and drug discovery advisory board with seasoned industry drug hunters and leading academic GPCR biology and pharmacology scientists.

Septerna, a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced that Jeffrey Finer, MD, PhD, has been named the company’s full-time Chief Executive Officer, transitioning from his current role as interim CEO.

Septerna, Inc., a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced its launch and Series A financing of $100 million. The Series A financing was led by Third Rock Ventures with significant support by Samsara BioCapital, BVF Partners, Invus Financial Advisors, Catalio Capital Management, Casdin Capital and Logos Capital. Septerna’s proprietary Native Complex™ Platform recapitulates GPCRs with their native structure, function, and dynamics outside of the cellular environment which enables industrial-scale drug discovery using novel screening technologies and structure-based drug design for the first time. Septerna is using the Native ComplexTM to overcome historic challenges of reaching the vast untapped potential of GPCR drug targets for a wide range of diseases.